Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small cell lung cancer.

G Rosti1, G Bevilacqua, P Bidoli

  • 1Medical Oncology, Ravenna, Italy. rosti@ra.nettuno.it

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|April 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026
Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025
Same author

A Healthy Conversation Skills intervention to support changes to physical activity and dietary behaviours in community-dwelling older adults during the COVID-19 pandemic.

Perspectives in public health·2024
Same author

Work and Retirement Among Women: The Health and Employment After Fifty Study.

Occupational medicine (Oxford, England)·2024
Same author

From farm to fork… and beyond! UV enhances Aryl hydrocarbon receptor-mediated activity of cruciferous vegetables in human intestinal cells upon colonic fermentation.

Food chemistry·2023
Same author

Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Small cell lung cancer (SCLC) treatment showed early promise with chemotherapy and radiation, but survival rates have plateaued. Despite new therapies, research is urgently needed to improve outcomes for this challenging lung cancer.

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Research

Background:

  • Small cell lung cancer (SCLC) constitutes 13-15% of global lung cancer cases.
  • Historically, SCLC demonstrated high sensitivity to chemotherapy and radiation therapy.
  • Recent decades show a plateau in treatment efficacy despite advancements.

Purpose of the Study:

  • To review the historical treatment landscape of SCLC.
  • To evaluate the impact of new chemotherapeutic agents and targeted therapies.
  • To highlight the urgent need for improved clinical research in SCLC.

Main Methods:

  • Review of established chemotherapy regimens (cisplatin-etoposide, cyclophosphamide-anthracycline-vincristine/etoposide).
  • Assessment of radiation therapy protocols, including prophylactic brain irradiation.

Related Experiment Videos

  • Evaluation of newer agents (gemcitabine, irinotecan, paclitaxel) and targeted therapies.

    • Main Results:

    • Initial SCLC treatments yielded 50-70% response rates and 20-30% complete remissions in extensive disease.
    • Limited stage SCLC achieved 10-20% cure rates with combined modality treatment.
    • Prophylactic brain irradiation reduced mortality by approximately 5% in limited stage SCLC.
    • Despite new agents, overall survival for SCLC remains largely unchanged.
    • Targeted therapy evaluations are premature and currently discouraging.

    Conclusions:

    • SCLC treatment efficacy has plateaued, necessitating novel therapeutic strategies.
    • Second-line therapies offer limited survival benefits.
    • There is a critical need to reinvigorate clinical research for SCLC to overcome current limitations.